Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Priya Nigam

HISTORICAL FACTS: Bofa downgrades ginkgo bioworks cuts price target in half | History Defined

While Ginkgo Bioworks Holdings Inc’s (NYSE:DNA) overall first-quarter results were better than expected, revenues and active programs in its core Foundry segment fell short of estimates, according to BofA Securities.

The Ginkgo Bioworks Analyst: Derik de Bruin downgraded the rating for Ginkgo Bioworks from Neutral to Underperform, while reducing the price target from $6 to $3.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.